Rasio utang jangka dawa marang modal Agilent Corp (A)

Simbol lan logo merek Agilent Technologies (A)

Agilent Technologies (A) new management is seamlessly continuing the strategic development vector while maintaining the stability of corporate processes. This chart of the long-term debt-to-equity ratio currently reflects a level of 0.50. The business generates revenue from the sale of diagnostic instruments and components for various industries, which minimizes sector-specific risks. The manufacturer's flawless reputation for precision equipment guarantees global recognition within the scientific community.

Agilent Technologies, Inc. (A): Utang jangka dawa marang ekuitas saka 04.07.2022 nganti 29.10.2026
Produk asli Agilent

This ratio compares long-term debt obligations to equity, revealing the extent to which financial stability depends on external borrowings amid changes in the market value of shares. The trend of the long-term debt-to-equity ratio reflects the strategy of Agilent Technologies (A) for financing the development of high-precision laboratory equipment, where the balance between cheap debt and equity determines the pace of technological upgrades in genetics and ecology.

Analisis perusahaan pesaing

Utang jangka dawa marang modal Quest Diagnostics Inc.|Utang jangka dawa marang ekuitas Illumina Corp (ILMN)|Exact Sciences Inc. - Rasio utang jangka dawa marang modal|Utang jangka dawa marang modal RVTY (Revvity, Inc.)|Utang jangka dawa marang modal bio-rad.com BIO|NNNN - Utang jangka dawa marang ekuitas|SHC: Utang jangka dawa marang ekuitas|QDEL (QuidelOrtho Corp) - Rasio utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal OPKO Health Corp. (OPK)|Utang jangka dawa marang ekuitas CareDx Inc|maravai.com (MRVI) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang modal FLGT|Rasio tanggungan utang jangka dawa marang modal Standard BioTools Inc|Utang jangka dawa marang ekuitas Cytek Bio CTKB|Rasio tanggungan utang jangka dawa marang modal OraSure Corp (OSUR)|Exagen Diagnostics - Utang jangka dawa marang modal|MDXH - Utang jangka dawa marang modal|LUCD: Utang jangka dawa marang modal|Tanggungan utang jangka dawa marang ekuitas Prenetics PRE|IMDX (Insight Molecular Diagnostics, Inc.) - Utang jangka dawa marang modal|Trinity Biotech Corp (TRIB) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas ProPhase Labs, Inc. (PRPH)|Utang jangka dawa marang ekuitas AIMD (ainos.com)|Utang jangka dawa marang modal CODX (Co-Diagnostics)|Heart Test Laboratories, Inc. (HSCS) - Kewajiban jangka dawa marang modal|BMRA - Utang jangka dawa marang ekuitas|CDIO (Cardio Diagnostics) - Rasio utang jangka dawa marang modal|VRAX (Virax Biolabs Group) - Rasio utang jangka dawa marang ekuitas|BJDX: Rasio silihan jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas AWH|AXDX: Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas CNTG (CENTOGENE, N.V.)|Rasio silihan jangka dawa marang modal ENZ|Utang jangka dawa marang modal FRES (Fresh2 Group)|Genetic Technologies Ltd (GENE) - Kewajiban jangka dawa marang modal|23andMe - Utang jangka dawa marang modal|Psychemedics Corp. (PMD) - Rasio utang jangka dawa marang ekuitas